Printer Friendly

The pollutant Diethylhexyl phthalate regulates hepatic energy metabolism via species-specific PPAR[alpha]-dependent mechanisms.

BACKGROUND: The modulation of energetic homeostasis by pollutants has recently emerged as a potential contributor to the onset of metabolic disorders. Diethylhexyl phthalate (DEHP) is a widely used industrial plasticizer to which humans are widely exposed. Phthalates can activate the three peroxisome proliferator--activated receptor (PPAR) isotypes on cellular models and induce peroxisome proliferation in rodents.

OBJECTIVES: In this study, we aimed to evaluate the systemic and metabolic consequences of DEHP exposure that have remained so far unexplored and to characterize the underlying molecular mechanisms of action.

METHODS: As a proof of concept and mechanism, genetically engineered mouse models of PPARs were exposed to high doses of DEHP, followed by metabolic and molecular analyses.

RESULTS: DEHP-treated mice were protected from diet-induced obesity via PPAR[alpha]-dependent activation of hepatic fatty acid catabolism, whereas the activity of neither PPAR[beta] nor PPAR[gamma] was affected. However, the lean phenotype observed in response to DEHP in wild-type mice was surprisingly abolished in PPAR[alpha]-humanized mice. These species differences are associated with a different pattern of coregulator recruitment.

CONCLUSION: These results demonstrate that DEHP exerts species-specific metabolic actions that rely to a large extent on PPAR[alpha] signaling and highlight the metabolic importance of the species-specific activation of PPAR[alpha] by xenobiotic compounds.

Key WORDS: DEHP, endocrine disruptor, metabolism, PPAR, species specificity. Environ Health Perspect 118:234-241 (2010). doi:10.1289/ehp.0901217 available via http://dx.doi.org/ [Online 8 October 2009]

**********

The prevalence of obesity and its associated metabolic complications has dramatically increased during the past decades; it has been suggested that this could, to some extent, be linked to the exposure to environmental pollutants, which coincidently increased during the same period (Baillie-Hamilton 2002; Grun and Blumberg 2007; Heindel 2003; Newbold et al. 2007). Endocrine disruptors constitute a wide class of chemicals that can affect human and animal populations by interfering with the synthesis, elimination, and mechanisms of action of hormones (Markey et al. 2002; Waring and Harris 2005). One of their key mechanisms of action is the modulation of gene expression programs by targeting the activity of a family of nuclear receptors that are activated by intracellular lipophilic hormones and mediators. The concept of endocrine disruption, which initially arose because of the interference with reproductive biology, is now gradually being broadened to other receptors implicated in different aspects of homeostasis (Tabb and Blumberg 2006).

Metabolic homeostasis requires a controlled balance between energy storage and use, and several nuclear receptors as well as their coregulators are instrumental in regulating these processes (Desvergne et al. 2006; Feige and Auwerx 2007). Among these, peroxisome proliferator--activated receptors (PPARs) play a prominent role by acting as lipid sensors that cooperate in different organs to adapt gene expression to a given metabolic status (Desvergne et al. 2004; Evans et al. 2004; Feige et al. 2006). PPAR[alpha] (NR1C1) is the founding member of the family and was initially isolated as the receptor inducing the hepatic proliferation of peroxisomes in rodents in response to synthetic chemicals. However, this function represents only a small subset of the physiologic functions regulated by this receptor. PPAR[alpha] and PPAR[beta]/[delta] (NR1C2, referred to here as PPAR[beta]) share partially overlapping functions in the control of catabolic metabolism by promoting fatty acid oxidation in tissues with high metabolic rates such as liver or muscle (Desvergne et al. 2004; Evans et al. 2004; Feige et al. 2006). In contrast, PPAR[gamma] (NR1C3) controls fat storage in adipose tissue by promoting differentiation and survival of adipocytes and also plays major roles in the control of insulin sensitivity (Lehrke and Lazar 2005).

Several endocrine disruptors, including pesticides, industrial solvents, and plasticizers, can activate PPARs in cellular models (Bility et al. 2004; Grun et al. 2006; Hurst and Waxman 2003; Kanayama et al. 2005; Lapinskas et al. 2005; Takeuchi et al. 2006). However, the metabolic consequences of PPAR activation by endocrine disruptors remain largely unknown, although some physiologic consequences are emerging, such as adipogenic action of organotins (Grun et al. 2006) and PPAR[alpha]-dependent induction of hepatic peroxisome proliferation by phthalates (Lapinskas et al. 2005; Ward et al. 1998). Diethylhexyl phthalate (DEHP) is among the phthalate esters most abundantly used as industrial plasticizers and is also found in cosmetics, as well as in industrial paints and solvents. DEHP is found in flexible plastics used for manufacturing a wide variety of daily products, including medical devices and food packaging, and its propensity to leach can lead to high levels of human exposure [National Toxicology Program Center for the Evaluation of Risks to Human Reproduction (NTP-CERHR) 2000]. When ingested through contaminated food, DEHP is converted by intestinal lipases to its monoester equivalent monoethylhexyl phthalate (MEHP), which is then preferentially absorbed (Huber et al. 1996). MEHP can then be metabolized into a myriad of secondary metabolites that can be excreted (Rusyn et al. 2006), among which 2-ethylhexanoic acid has also been reported as a low-affinity PPAR[alpha] activator (Lapinskas et al. 2005; Maloney and Waxman 1999). The biological effects of exposure to DEHP are hence of major concern, but their possible adverse effects on human health remain obscure.

These observations led us to investigate the molecular aspects of phthalate-mediated activation of PPAR[gamma]. In cellular models, MEHP induces adipogenesis by modulating PPAR[gamma] activity (Feige et al. 2007), suggesting that DEHP could promote obesity in vivo if its MEHP metabolite reaches adipose tissue accepted 8 October 2009. (Grun and Blumberg 2007; Heindel 2003). However, MEHP also activates PPAR[alpha] and PPAR[beta] in vitro (Bility et al. 2004; Feige et al. 2007; Hurst and Waxman 2003; Lapinskas et al. 2005), suggesting that DEHP exposure may also promote fatty acid oxidation. In the present study, we addressed the metabolic consequences of DEHP exposure in mice. Intriguingly, DEHP exposure protected mice from weight gain under both a regular diet and a diet containing high fat content; this effect could be attributed solely to the hepatic oxidative functions of PPAR[alpha]. The lean phenotype of DEHP-treated mice was not observed in mice humanized for PPAR[alpha] where the mouse receptor has been replaced by a human PPAR[alpha] (hPPAR[alpha]) transgene. At the molecular level, the functional differences between mouse PPAR[alpha] (mPPAR[alpha]) and hPPAR[alpha] are associated with a different pattern of coregulator recruitment in the presence of MEHP. Altogether, our observations highlight key physiopathologic consequences of chronic exposure to DEHP and highlight the metabolic importance of the species-specific metabolic consequences of PPAR[alpha] activation by xenobiotics compounds.

Materials and Methods

Animal experiments. We carried out DEHP exposure in wild-type (WT) mice using C57B16J mice (Charles River, L'Arbresle, France), which were fed a chow diet (CD) or a high-fat diet (HFD) containing 60% fat (Provimi-Kliba, Kaiseraugst, Switzerland), supplemented with 10 mL sunflower oil (vehicle) per kilogram of feed in the presence or absence of DEHP (Sigma Aldrich, Buchs, Switzerland). Genetically engineered mouse models are described in the Supplemental Material available online (doi:10.1289/ehp.0901217.Sl via http://dx.doi.org/). Animal experiments were conducted humanely and with regard for alleviation of suffering, and were approved by the relevant animal welfare commissions.

Metabolic phenotyping. We performed glucose tolerance tests after an intraperitoneal injection of 2 g glucose/kg body mass after 4 hr of fasting. Fat and lean body compositions were measured by nuclear magnetic resonance (NMR) on an Echo-MRI (magnetic resonance imaging) 100 apparatus (Echo Medical Systems, Houston, TX, USA). Indirect calorimetry in metabolic cages was performed with a Comprehensive Lab Animal Monitoring System (Columbus Instruments, Columbus, OH, USA) during 24 hr after a 36- to 48-hr acclimation period. The exercise test was performed on a treadmill (Columbus Instruments); a 6-min training period at low velocity was given 24 hr before the exercise (Feige et al. 2008; Lagouge et al. 2006). Mice were exercised until they reached fatigue [defined by resting for > 50% of the time on the shock pad; see Supplemental Material, Figure 2 (doi:10.1289/ehp.0901217.Sl)]. Biochemical assays and quantitative PCR (polymerase chain reaction) techniques are described in the Supplemental Material (doi:10.1289/ ehp.0901217.S1).

Reporter gene and pull-down assays. We performed PPAR luciferase-based reporter gene assays in C2C12 mouse myoblast cells using plasmids, compounds, and procedures described previously (Feige et al. 2005, 2007). Pull-downs using glutathione S-transferase (GST)-labeled coregulators and (35) S-labeled PPAR[alpha] produced in reticulocyte lysates were performed as described previously (Feige et al. 2005,2007) in the presence of vehicle, 100 [micro]M Wyl4643 (Cayman Chemicals, Ann Harbor, MI, USA), or 1,000 [micro]M MEHP (Imperial Chemical Industries, Slough, UK). The primary culture of hepatocytes and adenoviral infections are described in the Supplemental Materials (doi:10.1289/ehp.0901217.Sl).

Statistical analyses. All data are reported as mean [+ or -] SE. Results were considered statistically significant when p-vaiues were < 0.05 by unpaired two-tailed Student's t-test.

Results

DEHP exposure protects from obesity in mice. The ability of the DEHP metabolite MEHP to activate PPAR[alpha] and PPAR[beta], on the one hand, and PPAR[gamma] on the other, suggests that this endocrine disruptor could potentially influence the two arms of the energetic balance by affecting both energy expenditure and storage. To understand the global metabolic output of an exposure to DEHP, we fed WT C57B16J mice with a regular CD containing vehicle or DEHP. Animals were thereby exposed to the compound through intestinal absorption, a route that mimics one of the most frequent sources of exposure in humans and favors the conversion of DEHP to its major bioactive metabolite MEHP. DEHP was incorporated in the diet at two concentrations, leading to average exposures of 100 and 1,000 mg/kg body mass/day), dosages that were previously reported to be less than and greater than the minimal exposure required for hepatic peroxisome proliferation, respectively (David et al. 1999). The treatment started just after weaning at 3 weeks of age. At week 13, mice treated with 1,000 mg/kg/ day DEHP gained approximately 15% less weight than did controls or mice treated with 100 mg/kg/day; this difference did not result from different feeding behaviors because all three groups consumed the same amount of food (Figure 1A). Consistently, the lean mass measured by NMR was not affected by the treatment at either dose, but the weight difference at the high dose was solely caused by reduced total body fat (Figure 1B). Along the same line, the mass of the epididymal white adipose tissue (epiWAT) at sacrifice was also reduced by 40% (Figure 1C). Only the high dose of DEHP induced a hepatomegaly (Figure 1C), testifying that significant peroxisome and hepatocyte proliferation occurred only at 1,000 mg/kg/day (Rusyn et al. 2006). In the blood, triglyceride and free fatty acid levels were reduced in DEHP-treated mice (Figure 1D), suggesting that the reduced fat mass of these animals reflects enhanced fatty acid oxidation. DEHP treatment consistently increased plasma total ketone bodies, a marker of hepatic fatty acid oxidation. Plasma glucose levels were not affected by DEHP in fed or fasted animals (Figure 1D and data not shown, respectively). Although DEHP treatment did not modify glucose tolerance [see Supplemental Material, Figure 1 (doi: 10.1289/ ehp.0901217.Sl)], insulin levels were significantly lower in mice treated with 1,000 mg/ kg/day DEHP (Figure ID). Altogether, these results demonstrate that DEHP exposure reduces adiposity under CD.

To understand whether a diet high in fat would exacerbate or counterbalance this lean phenorype, we fed adult WT mice the HFD (containing 60% calories as fat) supplemented with vehicle or 500 mg/kg/day DEHP (Figure 2). The HFD alone led to a doubling of body mass (Figure 2A), essentially due to the increased fat mass from 8-10% of body mass before treatment (as measured by NMR), to 30% after 13 weeks of HFD, whereas fat mass remained at 8-10% after 13 weeks of CD (data not shown). DEHP strongly protected mice from HFD-induced obesity without affecting food intake (Figure 2A). Although hepatomegaly was observed in DEHP-treated mice because of PPARa-dependent peroxisome and hepatocyte proliferation (Rusyn et al. 2006), in vivo analyses of body composition revealed that the reduced body mass resulted from lower fat mass (Figure 2B,C). Consistent with its protective effect on adiposity, DEHP inhibited adipocyte hypertrophy and hepatic lipid droplet accumulation (Figure 2D). Despite peroxisome proliferation in hepatocytes in response to DEHP, the global histology of the liver was normal, with no signs of inflammation or necrosis (Figure 2D). The normal plasma levels of alanine aminotransferase and aspartate aminotransferase (Figure 2E), two markers of liver damage, further suggest that the lean phenotype of DEHP-treated mice is not the consequence of hepatic toxicity. In addition, the reduced adiposity did not result from a difference in lipid absorption or excretion, because lipid concentrations in the feces were not affected by the treatment (Figure 2F). DEHP exposure did not affect free fatty acid levels but significantly reduced triglyceride and increased ketone body concentrations, thereby suggesting a catabolic state primarily occurring in the liver (Figure 2G). As observed under the CD, insulin levels were also reduced in the blood of DEHP-treated animals, whereas glycemia was not affected.

Metabolic phenotyping of DEHP-treated mice. Indirect calorimetry revealed that DEHP treatment increases oxygen consumption and carbon dioxide release both during day and night (Figure 3A), thus providing evidence of an increased metabolic rate in DEHP-treated mice. However, the fuel preference was not modified by the exposure to DEHP because the respiratory exchange ratio [ratio between carbon dioxide ([CO.sub.2]) release and oxygen ([O.sub.2]) consumption] was not affected. Although the protective effect of DEHP on body weight gain was not a consequence of increased spontaneous locomotor activity (Figure 3A), we evaluated muscle

The active DEHP metabolite MEHP can activate the three PPAR isotypes, of which PPAR[gamma] plays a crucial role in controlling insulin sensitivity (Lehrke and Lazar 2005). A full PPAR[gamma] activation seems unlikely in DEHP-treated mice because PPAR[gamma] activation by full agonists such as thiazolidinediones promotes adipogenesis and weight gain. However, we recently reported that MEHP acts as a selective PPAR[gamma] modulator (Feige et al. 2007), a class of compounds capable of uncoupling the action of PPAR[gamma] on adipogenesis from those on insulin sensitivity and glucose tolerance (Gelman et al. 2007). We therefore measured glucose tolerance and found that DEHP administration mildly enhanced glucose tolerance (Figure 3C). However, given the detrimental action of adiposity on glucose tolerance, this effect is most likely a consequence of the lean phenotype rather than of PPAR[gamma] activation.

DEHP activates hepatic fatty acid oxidation through PPAR[alpha]. One key question to fully understand the metabolic consequences of DEHP exposure is the individual responses of organs controlling energy expenditure and storage. Because MEHP can activate the three PPAR isotypes in cellular systems, all PPAR-expressing tissues are potential targets if they are exposed to MEHP upon DEHP ingestion. We thus measured the expression of well-characterized PPAR target genes (Figure 4). In the liver, DEHP exposure induced the expression of genes implicated in various aspects of fatty acid oxidation, including mitochondrial [beta]-oxidation (medium chain acylCoA dehydrogenase; MCAD), peroxisomal [beta]-oxidation (AcylCoA oxidase 1; ACOX), intracellular fatty acid shuttling (fatty acid binding protein 1; FABP-1), and mitochondrial fatty acid import (carnitine palmitoyl transferase la; CPT-1a) (Figure 4A). Strikingly, DEHP also robustly induced the hepatic expression of fibroblast growth factor 21 (FGF-21), a gene recently described to control lipid oxidation and ketogenesis in the liver and lipolysis in the adipose tissue (Badman et al. 2007; Inagaki et al. 2007; Kharitonenkov et al. 2005). These gene profiling experiments were functionally confirmed by the biochemical measurement of hepatic hydroxyacyl-CoA dehydrogenase activity, which demonstrated that fatty acid oxidation was increased in the liver of DEHP-treated mice (Figure 4E). Because PPAR[alpha] is the most prominent hepatic PPAR isotype and all five of the genes we tested are reported to be under the direct transcriptional control of PPAR[alpha], these observations suggested that the lean phenotype of DEHP-treated mice results at least in part from hepatic fatty acid oxidation mediated by PPAR[alpha]. Other energy-dissipating tissues expressing PPARs do not seem to contribute to this phenotype as oxidative target genes in skeletal muscle [long chain acyl-CoA dehydrogenase (LCAD) and pyruvate dehydrogenase kinase 4 (PDK4)] and in brown adipose tissue [uncoupling protein 1 (UCP1) and PPAR[gamma] coactivator 1[alpha] (PGC-1[alpha])] were not affected (Figure 4B,D). In addition, the expression of adipogenic target genes under direct transcriptional control of PPAR[gamma] in white adipose tissue (WAT) was not affected (Figure 4C). These gene expression data therefore demonstrate that DEHP exposure does not affect adipogenesis in vivo and drives a catabolic response occurring primarily in the liver, most probably through activation of PPAR[alpha].

Because the oxidative functions of PPAR[alpha] and PPAR[beta] partially overlap, we dissected the contribution of each individual receptor by feeding PPAR[alpha]- and PPAR[beta]-null mice the HFD supplemented with DEHP. We observed the protective effects of DEHP on weight gain in WT mice as well as in PPAR[beta]-null mice (Figure 5A,B). In contrast, DEHP did not influence the body mass of PPAR[alpha]-null mice (Figure 5A), demonstrating that the anti-obesity action of DEHP requires PPAR[alpha] only. This conclusion was further corroborated by reduced fat mass after DEHP exposure in PPAR[beta]-null mice but not PPAR[alpha]-null mice (Figure 5C-F). Similarly, the DEHP-dependent hepatomegaly caused by peroxisome proliferation was PPAR[alpha]- but not PPAR[beta]-dependent (Figure 5E,F). PPAR[alpha] was also indispensable to the hepatic induction of oxidative gene expression after DEHP exposure (Figure 5G), whereas the influence of PPAR[beta]. was modest to nonexistent based on the genes analyzed (Figure 5H). To further demonstrate the role of hepatic PPAR[alpha] in the response to DEHP, we isolated primary hepatocytes from WT and PPAR[alpha]-null mice and showed that only WT hepatocytes were responsive to MEHP. In addition, the lack of response to MEHP in PPAR[alpha]-null hepatocytes was restored by adenoviral-mediated over-expression of PPAR[alpha] (Figure 51). Altogether, these results demonstrate that DEHP protects from obesity by activating the catabolic functions of PPAR[alpha] in the liver.

DEHP protects WT mice but not humanized models from obesity. The identification of hepatic PPAR[alpha]-dependent activation as the cause of the lean phenotype of DEHP-treated mice raises the question of how this protective action may translate to humans exposed to DEHP. In mice, peroxisome and hepatic proliferation is directly controlled by PPARa[alpha] activation and coexists with metabolic actions of the receptor on fatty acid oxidation, whereas only the actions on fatty acid oxidation extend to humans. To overcome this dual role of PPAR[alpha] in mice, we analyzed the action of DEHP on HFD in a humanized mouse model of PPAR[alpha] that is insensitive to hepatocellular proliferation (Yang et al. 2008). In this model, the entire human PPAR[alpha] gene and its regulatory regions were introduced into the mPPAR[alpha] null background, thereby allowing the expression, regulation, and function of human PPAR[alpha] in the mouse. Although DEHP limited weight gain in WT mice as shown above, PPAR[alpha]-humanized mice were not protected against diet-induced obesity (Figure 6A), demonstrating that this beneficial effect is limited to mPPAR[alpha] activation. Indeed, and as expected, humanized PPAR[alpha] mice did not develop the DEHP-induced hepatomegaly caused by cell proliferation (Figure 6B), but presented a slight excess of adiposity upon DEHP exposure. This was evidenced by an increase in total body mass and in epiWAT (Figure 6A,B). We thus evaluated gene expression in the liver and WAT to understand how DEHP may promote fat accumulation in humanized PPAR[alpha] mice. Strikingly, although this PPAR[alpha]-humanized mice model can respond to a classic PPAR[alpha] agonist (Yang et al. 2008), we observed no activation of the genes and enzymatic activities controlling hepatic [beta]-oxidation in response to DEHP (Figure 6C,D). The fact that DEHP-treated PPAR[alpha]-humanized mice gained more weight than did their untreated counterparts was furthermore not caused by enhanced adipogenesis and fat storage via PPAR[gamma] activation in WAT because the expression of direct adipogenic PPAR[gamma] target genes was not modified (data not shown). Altogether, these results demonstrate that the protective effects of DEHP on weight gain are dependent on the species origin of the PPAR[alpha] receptor and most probably do not extend to humans, in which the metabolic consequences of DEHP exposure, if any, should rather be detrimental.

According to the humanized mouse model used in this study, the mechanism involved in the species-specific response to DEHP seems to rely solely on differences in the receptor itself. To understand the molecular basis of this differential action, we first evaluated the ability of mPPAR[alpha] and hPPAR[alpha] to activate the PPAR response element of a reporter construct in the presence of the full PPAR agonist Wy14643 or of MEHP, the active metabolite of DEHP (Figure 7A). In this assay, MEHP treatment resulted in a maximal activation of mPPAR[alpha] and hPPAR[alpha] to a similar extent, despite having a slightly higher affinity for the mouse than for the human receptor, as previously observed (Bility et al. 2004; Hurst and Waxman 2003). To further analyze what could be the functional consequence of the subtle conformational differences of mPPAR[alpha] versus hPPAR[alpha], we tested their ability to interact with coregulators in the absence of ligand or upon binding of Wy14643 or MEHP (Figure 7B). In the presence of Wy14643, mPPAR[alpha] and hPPAR[alpha] shared a similar pattern of interaction with coregulators, releasing NCoR (nuclear receptor co-repressor 1) and efficiently recruiting Medl (mediator complex subunit 1), PGC-1[alpha] (peroxisome proliferator-activated receptor-[alpha] coactivator 1[alpha]), and to a lower extent p300 (E1A binding protein p300). In contrast, MEHP induced a partial release of NCoR with both the mouse and the human receptor but failed to induce the ligand-dependent recruitment of the coactiva-tors Medl, p300, and PGC-1[alpha] to mPPAR[alpha]. In contrast, all three coactivators were efficiently recruited by the human receptor in the presence of MEHP, at a level very close to that obtained with Wy14643. Together with the experiments in the humanized PPAR[alpha] mouse model, these in vitro observations suggest that subtle differences in the mPPAR[alpha] and hPPAR[alpha] receptors contribute to a species-specific PPAR[alpha]-dependent metabolic response to DEHP.

Discussion

DEHP protects from diet-induced obesity in WT mice via hepatic PPAR[alpha] activation. DEHP is the most widely used industrial plasticizer, and human exposure to this pollutant is high through the daily use of polyvinyl chloride products (NTP-CERHR 2000). Mice fed either CD or HFD supplemented with DEHP were partially protected from diet-induced obesity because they gained 30% less weight than did their controls without modifying their feeding behavior. This reduced weight gain resulted solely from reduced fat mass and was associated with a metabolic improvement, which includes lower levels of triglycerides in the liver and the blood, smaller adipocytes, and enhanced glucose tolerance. Using a combination of metabolic phenotyping, metabolomics, gene expression profiling, and genetically engineered mouse models, we could attribute this phenotype primarily to a PPAR[alpha]-dependent activation of fatty acid catabolism in the liver. DEHP induced the expression of genes controlling [beta]-oxidation of fatty acids in the liver as well as that of FGF-21, a novel PPAR[alpha] target important for lipid oxidation and ketogenesis (Badman et al. 2007; Inagaki et al. 2007). We demonstrated that PPAR[alpha] was required for the protective effect of DEHP by showing that both the protection from diet-induced obesity and the induction of oxidative genes in the liver were completely abolished in PPAR[alpha]-null mice. Although our results clearly demonstrate DEHP-mcdiated metabolic interference via PPAR[alpha], other metabolic pathways--such, as those driven by CAR (constitutive androstane receptor) and Rev-Erb[alpha] (nuclear receptor subfamily 1, group D, member 1)--could also be involved (Eveillard et al. 2009).

Unlike what has been hypothesized from the ability of MEHP to activate PPAR[gamma] and promote adipogenesis in cellular models (Bility et al. 2004; Feige et al. 2007; Grun and Blumberg 2007; Heindel 2003; Hurst and Waxman 2003), we found that DEHP exposure does not cause PPAR[gamma] activation and fat accumulation in the adipose tissue of WT mice. The reasons for this observation remain unclear because MEHP has been detected as the major metabolite in the blood of rats treated with doses of DEHP in the same range as those used in the present study (Akingbemi et al. 2004). In those animals, circulating MEHP concentrations were around 10 [micro]M (Akingbemi et al. 2004), a level at which PPAR[gamma] can be activated by MEHP in cellular assays (Feige et al. 2007). Moreover, in our previous study (Feige et al. 2007), the levels of MEHP in the blood were sufficient to induce the hepatic activation of PPAR[alpha], an activation that occurs at similar concentrations for PPARa and PPAR[gamma]. Thus, the most likely hypothesis is that MEHP cannot enter adipocytes in sufficient concentrations to activate PPAR[gamma].

DEHP exacerbates diet-induced obesity in a humanized PPAR[alpha] mouse model. It is well established that DEHP is a potent inducer of hepatocellular and peroxisome proliferation in rodents through PPAR[alpha] activation by MEHP (Rusyn et al. 2006) and that these proliferative processes do not occur in humans after PPAR[alpha] activation (Holden and Tugwood 1999). To overcome this limitation and to evaluate the effects of DEHP in a model more relevant to humans, we administered DEHP to mice humanized for PPAR[alpha] (i.e., expressing the human PPAR[alpha] receptor in the mPPAR[alpha] null background) that do not exhibit hepatocellular proliferation but whose PPAR[alpha]-dependent oxidative functions remain intact (Cheung et al. 2004; Yang et al. 2008). Strikingly, the metabolic actions of DEHP were abolished in this mouse model, which actually tended to be more sensitive to diet-induced obesity than were untreated controls. This unexpected phenotype may relate to two main cellular defects. First, it is possible that hepatocellular proliferation and the resultant hepatomegaly itself are important metabolic contributors. Second, and more specifically, genes responsible for fatty acid oxidation are not up-regulated in the liver of DEHP-treated humanized PPAR[alpha] mice, whereas they are markedly induced in response to synthetic PPAR[alpha] agonists.

Although MEHP induced a similar trans-activation of mPPAR[alpha] and hPPAR[alpha] in cellular models, it actually induced stronger interactions with coactivators with the human receptor than with the mouse receptor in GST pull-downs. It is therefore surprising that the induction of PPAR[alpha] target genes by DEHP exposure is blunted in PPAR[alpha]-humanized mice. However, interactions with coregula-tors depend highly on the promoter context (Guan et al. 2005), and the regulation of genes crucial to metabolic homeostasis could potentially involve promoter-specific interactions with coregulators. Because activation of PPAR[alpha] was recently reported to repress Let7C microRNA in WT but not in humanized PPAR[alpha] mice (Shah et al. 2007; Yang et al. 2008), the blunted response to DEHP in PPAR[alpha]-humanized mice may also reflect a dependency on this microRNA-mediated response. However, these hypotheses do not exclude the possibility that secondary MEHP metabolites could also play important roles in the metabolic actions of DEHP by differentially activating hPPAR[alpha] and mPPAR[alpha].

Considerations regarding the metabolic consequences of DEHP exposure in humans. The extrapolation of the action of DEHP from animal models to humans is definitely a complex issue that depends both on the relative levels of exposure and on the conservation of the underlying molecular mechanisms of action between species. Our studies involved relatively high levels of DEHP exposure, which were chosen according to previous reports of DEHP administration in rodents (David et al. 1999; Lapinskas et al. 2005). These doses are 2 to 3 orders of magnitude greater than estimated human exposures when normalized to body mass (NTP-CERHR 2000). However, the extrapolation of biological observations from rodents to humans is not linear to body mass, and levels of mouse exposure similar to those used herein lead to plasmatic MEHP concentrations in the low micromolar range (Akingbemi et al. 2004). Moreover, individuals requiring frequent blood transfusion or dialysis are subjected to repetitive acute exposures to high levels of DEHP because of the leaching of the compound from plastic bags and tubing in direct contact with biological fluids. Under such circumstances, the plasma levels of MEHP can also reach the micromolar range in humans (NTP-CERHR 2000), suggesting that the metabolic consequences of DEHP exposure described here may extend to humans. Thus, the most relevant observation is that DEHP slightly promotes weight gain in PPAR[alpha]-humanized mice. Consistent with this observation, the urinary concentrations of phthalate metabolites have been recently positively correlated with obesity and insulin resistance in humans (Hatch et al. 2008; Stahlhut et al. 2007). Our results clearly demonstrate that these effects are most likely not linked to activation of PPAR[gamma] and adipogenesis in the adipose tissue but potentially to low hepatic oxidative metabolism.

Conclusion

Altogether, our results demonstrate that exposure to the environmental pollutant DEHP has far-reaching metabolic consequences that rely on hepatic oxidative metabolism via PPAR[alpha] activation. Furthermore, our study also highlights a species-specific relationship between exposure to DEHP and diet-induced obesity.

REFERENCES

Akingbemi BT, Ge R, Klinefelter GR, Zirkin BR, Hardy MP. 2004. Phthalate-induced Leydig cell hyperplasia is associated with multiple endocrine disturbances. Proc Natl Acad Sci USA 101(3):775-780.

Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. 2007. Hepatic fibroblast growth factor 21 is regulated by PPAR[alpha] and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 5(6):426-437.

Baillie-Hamilton PF. 2002. Chemical toxins: a hypothesis to explain the global obesity epidemic. J Altern Complement Med 8(21:185-192.

Bility MT, Thompson JT, McKee RH, David RM, Butala JH, Vanden Heuvel JP, et al. 2004. Activation of mouse and human peroxisome proliferator-activated receptors (PPARs) by phthalate monoesters. Toxicol Sci 82(1): 170-182.

Cheung C, Akiyama TE, Ward JM, Nicol CJ, Feigenbaum L, Vinson C, et al. 2004. Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated receptor a. Cancer Res 64(11):3849-3854.

David RM, Moore MR, Cifone MA, Finney DC, Guest D. 1999. Chronic peroxisome proliferation and hepatomegaly associated with the hepatocellular tumorigenesis of di(2-ethylhexyllphthalate and the effects of recovery. Toxicol Sci 50(2):195-205.

Desvergne B, Michalik L, Wahli W. 2004. Be fit or be sick: peroxisome proliferator-activated receptors are down the road. Mol Endocrinol 18(6):1321-1332.

Desvergne B, Michalik L, Wahli W. 2006. Transcriptional regulation of metabolism. Physiol Rev 86(2):465-514.

Evans RM, Barish GD, Wang YX. 2004. PPARs and the complex journey to obesity. Nat Med 10(4):355-361.

Eveillard A, Lasserre F, de Tayrac M, Polizzi A, Claus S, Canlet C, et al. 2009. Identification of potential mechanisms of toxicity after di-(2-ethylhexyl)-phthalate (DEHP) adult exposure in the liver using a systems biology approach. Toxicol Appl Pharmacol 236(3):282-292.

Feige JN, Auwerx J. 2007. Transcriptional coregulators in the control of energy homeostasis. Trends Cell Biol 17(6):292-301.

Feige JN, Gelman L, Michalik L, Desvergne B, Wahli W. 2006. From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res 45(2):120-159.

Feige JN, Gelman L, Rossi D, Zoete V, Metivier R, Tudor C, et al. 2007. The endocrine disruptor monoethyl-hexyl-phthalate is a selective peroxisome peroxisome proliferator-activated receptor [gamma] modulator that promotes adipogenesis. J Biol Chem 282:19152-19166.

Feige JN, Gelman L, Tudor C, Engelborghs [gamma], Wahli W, Desvergne B. 2005. Fluorescence imaging reveals the nuclear behavior of peroxisome proliferator-activated receptor/retinoid X receptor heterodimers in the absence and presence of ligand. J Biol Chem 280(18): 17880-17890.

Feige JN, Lagouge M, Canto C, Strehle A, Houten SM, Milne JC, et al. 2008. Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab 8(5):347-358.

Gelman L, Feige JN, Desvergne B. 2007. Molecular basis of selective PPAR[gamma] modulation for the treatment of type 2 diabetes. Biochim Biophys Acta 1771(8):1094-1107.

Grun F, Blumberg B. 2007. Perturbed nuclear receptor signaling by environmental obesogens as emerging factors in the obesity crisis. Rev Endocr Metab Disord 8(2):161-171.

Grun F, Watanabe H, Zamanian Z, Maeda L, Arima K, Cubacha R, et al. 2006. Endocrine-disrupting organotin compounds are potent inducers of adipogenesis in vertebrates. Mol Endocrinol 20(9):2141-2155.

Guan HP, Ishizuka T, Chui PC, Lehrke M, Lazar MA. 2005. Corepressors selectively control the transcriptional activity of PPARy in adipocytes. Genes Dev 19(4):453-461.

Hatch EE, Nelson JW, Qureshi MM, Weinberg J, Moore LL, Singer M, et al. 2008, Association of urinary phthalate metabolite concentrations with body mass index and waist circumference: a cross-sectional study of NHANES data, 1999-2002. Environ Health 7:27; doi: 10.1186/1476-069X-7-27 [Online 3 June 2008].

Heindel JJ. 2003. Endocrine disruptors and the obesity epidemic. Toxicol Sci 76(2):247-249.

Holden PR.Tugwood JD. 1999. Peroxisome proliferator-activated receptor alpha: role in rodent liver cancer and species differences. J Mol Endocrinol 22(1):1-8.

Huber WW, Grasl-Kraupp B, Schulte-Hermann R. 1996. Hepatocarcinogenic potential of di(2-ethylhexyl)phthalate in rodents and its implications on human risk. Crit Rev Toxicol 26(4):365-481.

Hurst CH, Waxman DJ. 2003. Activation of PPAR[alpha] and PPAR[gamma] by environmental phthalate monoesters. Toxicol Sci 74(2):297-308.

Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Parameswara V, et a|. 2007. Endocrine regulation of the fasting response by PPAR[alpha]-mediated induction of fibroblast growth factor 21. Cell Metab 5(6):415-425.

Kanayama T, Kobayashi N, Mamiya S, Nakanishi T, Nishikawa J. 2005. Organotin compounds promote adipocyte differentiation as agonists of the peroxisome proliferator-activated receptor [gamma]/retinoid X receptor pathway. Mol Pharmacol 67(3):766-774.

Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, et al. 2005. FGF-21 as a novel metabolic regulator. J Clin Invest 115(6):1627-1635.

Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, et al. 2006. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRTl and PGC-l[alpha]. Cell 127(6):1109-1122.

Lapinskas PJ, Brown S, Leesnitzer LM, Blanchard S, Swanson C, Cattley RC, et al. 2005. Role of PPAR[alpha] in mediating the effects of phthalates and metabolites in the liver. Toxicology 207(l):l49-163.

Lehrke M, Lazar MA. 2005. The many faces of PPAR[gamma]. Cell 123(6):993-999.

Maloney EK, Waxman DJ. 1999. trans-Activation of PPAR[alpha] and PPAR[gamma] by structurally diverse environmental chemicals. Toxicol Appl Pharmacol 161(2):209-218.

Markey CM, Rubin BS, Soto AM, Sonnenschein C. 2002. Endocrine disruptors: from Wingspread to environmental developmental biology. J Steroid Biochem Mol Biol 83(1-5):235-244.

Newbold RR, Padilla-Banks E, Snyder RJ, Phillips TM, Jefferson WN. 2007. Developmental exposure to endocrine disruptors and the obesity epidemic. Reprod Toxicol 23(3):290-296.

NTP-CERHR (National Toxicology Program Center for the Evaluation of Risks to Human Reproduction). 2000. NTP-CERHR Expert Panel Report on Di(2-Etbylbexyl) Phthalate. Available: http://cerhr.niehs.nih.gov/chemicals/ dehp/DEHP-final.pdf [accessed 18 December 2009],

Rusyn I, Peters JM, Cunningham ML. 2006. Modes of action and species-specific effects of di-(2-ethylhexyl)phthalate in the liver. Crit Rev Toxicol 36(5):459-479.

Shah[gamma]M, Morimura K, Yang Q, Tanabe T, Takagi M, Gonzalez FJ. 2007. Peroxisome proliferator-activated receptor a regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferation. Mol Cell Biol 27(12):4238-4247.

Stahlhut RW, van Wijngaarden E, Dye TD, Cook S, Swan SH. 2007. Concentrations of urinary phthalate metabolites are associated with increased waist circumference and insulin resistance in adult U.S. males. Environ Health Perspect 115:876-882.

Tabb MM, Blumberg B. 2006. New modes of action for endocrine-disrupting chemicals. Mol Endocrinol 20(3):475-482.

Takeuchi S, Matsuda T, Kobayashi S, Takahashi T, Kojima H. 2006. In vitro screening of 200 pesticides for agonistic activity via mouse peroxisome proliferator-activated receptor (PPAR)a and PPAR[gamma] and quantitative analysis of in vivo induction pathway. Toxicol Appl Pharmacol 217(3):235-244.

Ward JM, Peters JM, Perella CM, Gonzalez FJ. 1998. Receptor and nonreceptor-mediated organ-specific toxicity of di(2-ethylhexyl)phthalate (DEHP) in peroxisome proliferator-activated receptor alpha-null mice. Toxicol Pathol 26(2):240-246.

Waring RH, Harris RM. 2005. Endocrine disrupters: a human risk? Mol Cell Endocrinol 244(1-2):2-9.

Yang Q, Nagano T, Shah [gamma], Cheung C, Ito S, Gonzalez FJ. 2008. The PPAR[alpha]-humanized mouse: a model to investigate species differences in liver toxicity mediated by PPAR[alpha]. Toxicol Sci 101(1):132-139.

Jermome N. Feige, (1) Alan Gerber, (1) Cristina Casals-Casas, (1) Carine Winkler, (1) Elodie Bedu, (1) Manual Bueno, (1) Laurnet Gelman, (1) Johan Auwerx, (3) Frank J. Gonzalez, (2) and Beatrice Desvergne (1)

(1) Center for Integrative Genomics, National Research Center "Frontiers in Genetics," University of Lausanne, Lausanne, Switzerland; (2) Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA; (3) Ecole Polytechnique Federale de Lausanne, Lausanne, Switzerland

Address correspondence to B. Desvergne, Center for Integrative Genomics, Le Genopode, Universite de Lausanne, CH-1015 Lausanne, Switzerland. Telephone: 41-0-21-692-41-40. Fax: 41-0-21-692-41-15. E-mail: beatrice.desvergne@unil.ch

Supplemental Material is available online (doi: 10.1289/ehp.0901217.S1 via http://dx.doi.org/).

We thank E. Joye, A. Hiou-Feige, and T. Meyer for experimental assistance; the DNA array facility and the mouse metabolic evaluation facility of the University of Lausanne for technical support; and J. Reddy for the peroxisome proliferator-activated receptor-[alpha] adenoviruses.

This work was supported by grants from the Swiss National Science Foundation (PNR50 to B.D.) and the National Cancer Institute Intramural Research Program (F.J.G.).

The authors declare they have no competing financial interests.

Received 18 July 2009;
COPYRIGHT 2010 National Institute of Environmental Health Sciences
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research; peroxisome proliferator--activated receptor
Author:Feige, Jerome N.; Gerber, Alan; Casals-Casas, Cristina; Yang, Qian; Winkler, Carine; Bedu, Elodie; B
Publication:Environmental Health Perspectives
Article Type:Report
Geographic Code:4EXSI
Date:Feb 1, 2010
Words:6313
Previous Article:Association of perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) with uric acid among adults with elevated community exposure to...
Next Article:Organic and inorganic mercury in neonatal rat brain after prenatal exposure to methylmercury and mercury vapor.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters